We previously reported that TAT-Cx43266–283 reduces GSC invasion in vitro35 and in vivo36 through Src-FAK axis, which may be the mechanism underlying the reduction of tumor infiltration found in the present study in TAT-Cx43266–283-treated GBMs originated by SVZ-NSCs with EGFR alterations and GBM driver mutations. This evidence concerns the gene PTK2 and neoplasm.